SCHEMBL20715468

SCHEMBL20715468

CC(C)Cc1ccc(NCCN2CCOCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
MALT1 Q9UDY8 1/20 0.47
TSHR P16473 1/20 0.46
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
ALOX15 P16050 1/20 0.45
ALOX12 P18054 1/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SIGMAR1 Q99720 1/20 0.44
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
TLR9 Q9NR96 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13547569 0.84 TRPC5 (0.49) ALDH1A1KMT2AKDM4EMEN1MAPT
SCHEMBL24324971 0.81 SIGMAR1 (0.47) KMT2AKDM4EMEN1SIGMAR1LMNA
SCHEMBL13841388 0.80 TSHR (0.60) TSHRKMT2AKDM4EMEN1SMN1; SMN2
SCHEMBL19234903 0.80 LMNA (0.48) TSHRKMT2AMEN1SMN1; SMN2GAA
SCHEMBL19234914 0.80 LMNA (0.48) TSHRKMT2AMEN1SMN1; SMN2GAA
SCHEMBL19234910 0.80 LMNA (0.48) TSHRKMT2AMEN1SMN1; SMN2GAA
SCHEMBL19234948 0.79 LMNA (0.47) TSHRKMT2AKDM4EMEN1SMN1; SMN2
SCHEMBL8245365 0.79 KMT2A (0.65) ALDH1A1KMT2AKDM4EMEN1SMN1; SMN2
SCHEMBL26964867 0.78 KMT2A (0.46) KMT2AKDM4EMEN1MAPTL3MBTL1
SCHEMBL8244325 0.78 CD274 (0.67) ALDH1A1KMT2AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2022-04-14 US disclosed
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2022-03-22 US disclosed
US-20190040102-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2019-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 ALDH1A1 4077/4885MALT1 4487/4885TSHR 34/4885
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 ALDH1A1 4110/4885MALT1 4500/4885TSHR 34/4885
US-20190040102-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 ALDH1A1 4077/4885MALT1 4487/4885TSHR 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.